Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease
Open Access
- 25 July 2007
- journal article
- research article
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 27 (30), 7899-7910
- https://doi.org/10.1523/jneurosci.1396-07.2007
Abstract
Huntington's disease (HD) is a neurodegenerative disorder caused by polyglutamine (polyQ) expansion in Huntingtin protein (Htt). PolyQ expansion in Httexpcauses selective degeneration of striatal medium spiny neurons (MSNs) in HD patients. Striatal MSN neurons receive glutamatergic input from the cortex and dopaminergic input from the substantia nigra. In previous studies with the yeast artificial chromosome (YAC128) transgenic HD mouse model, we established a connection between glutamate receptor activation, disturbed calcium (Ca2+) signaling, and apoptosis of HD MSNs (Tang et al., 2005). Here, we used the same YAC128 mouse model to investigate the role of dopaminergic signaling in HD. We discovered that glutamate and dopamine signaling pathways act synergistically to induce elevated Ca2+signals and to cause apoptosis of YAC128 MSNsin vitro. We demonstrated that potentiating effects of dopamine are mediated by D1-class dopamine receptors (DARs) and not by D2-class DARs. Consistent within vitrofindings, in whole-animal experiments we found that persistent elevation of striatal dopamine levels exacerbated the behavioral motor deficits and MSN neurodegeneration in YAC128 mice. We further discovered that the clinically relevant dopamine pathway inhibitor tetrabenazine alleviated the motor deficits and reduced striatal cell loss in YAC128 mice. Our results suggest that dopamine signaling pathway plays an important role in HD pathogenesis and that antagonists of dopamine pathway such as tetrabenazine or dopamine receptor blockers may have a therapeutic potential for treatment of HD beyond well established “symptomatic” benefit.Keywords
This publication has 61 references indexed in Scilit:
- Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trialNeurology, 2007
- Deranged neuronal calcium signaling and Huntington diseaseBiochemical and Biophysical Research Communications, 2004
- Dopamine Receptor-mediated Ca2+ Signaling in Striatal Medium Spiny NeuronsOnline Journal of Public Health Informatics, 2004
- Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's diseaseMolecular and Cellular Neuroscience, 2004
- Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutaminesNature Neuroscience, 2002
- Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas A PET studyBrain, 1995
- Determination of Fura-2 dissociation constants following adjustment of the apparent Ca-EGTA association constant for temperature and ionic strengthCell Calcium, 1991
- Nigral dopamine type-1 receptors are reduced in Huntington's disease: A postmortem autoradiographic study using [3H]SCH 23390 and correlation with [3H]forskolin bindingExperimental Neurology, 1990
- Organization of dopamine D1 and D2 receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophreniaSynapse, 1988
- PREDICTIVE TEST FOR HUNTINGTON'S CHOREAThe Lancet, 1970